Table 2. Thrombolytic Therapy Metrics and Hospital Characteristics by Anticoagulant Therapy Status Prior to Stroke.

	Taking NOACs (n = 2207)	Not taking anticoagulants (n = 160 831)	Absolute standardized differencea
Thrombolytic therapy metrics
Time, median (IQR), min
Onset-to-needle	122 (89-168)	123 (91-168)	1.9
Door-to-needle	51 (37-69)	49 (36-66)	7.7
Onset-to-arrival	62 (40-102)	64 (42-106)	6.5
Received endovascular therapy, No. (%)	415 (18.8)	18 526 (11.5)	20.4
Presence of large vessel occlusion, No./total (%)b	532/1214 (43.8)	25 291/76 322 (33.1)	22.1
Site of occlusion, No. (%)b	(n = 532)	(n = 25 276)
Middle cerebral artery	442 (83.1)	19 022 (75.3)	19.4
Internal carotid artery	69 (13.0)	4737 (18.7)	15.9
Other cerebral artery branch	41 (7.7)	2359 (9.3)	5.8
Basilar artery	16 (3.0)	904 (3.6)	3.2
Vertebral artery	9 (1.7)	1054 (4.2)	14.7
Hospital characteristics
No. of beds, median (IQR)	411 (278-620)	384 (255-585)	6.8
Annual ischemic stroke volume, median (IQR)	368 (232-563)	331 (211-530)	8.8
Annual intravenous thrombolytic therapy cases, median (IQR)	51 (30-82)	46 (26-73)	13.5
Academic hospital, No. (%)	1663 (75.4)	122 631 (76.2)	2.1
Stroke center status, No. (%)
Comprehensive	278 (12.6)	19 577 (12.2)	1.3
Primary	1162 (52.7)	88 717 (55.2)	5.0
Neither comprehensive nor primary	767 (34.8)	52 537 (32.7)	4.4
Geographic region, No. (%)
South	1010 (45.8)	66 393 (41.3)	9.1
West	503 (22.8)	34 935 (21.7)	2.6
Northeast	373 (16.9)	29 647 (18.4)	4.0
Midwest	321 (14.5)	29 856 (18.6)	10.8
Rural location, No. (%)	41 (1.9)	3800 (2.4)	3.5

Abbreviation: NOACs, non–vitamin K antagonist oral anticoagulants.

^a Calculated as the difference in means or proportions divided by a pooled estimate of the SD and multiplied by 100.

^b Not available in the registry until 2019.